Targeting a diverse spectrum of cancers.
Kinase switch control inhibitors for tumor-targeted and immune-targeted cancer therapies.
Deciphera’s proprietary switch control platform has generated a diverse clinical pipeline of kinase inhibitor drug candidates including tumor-targeted therapies and immuno-targeted therapies.
03/19/18 4:00 PM EDT
© Nasdaq. Minimum 15 minutes delayed.
Deciphera Pharmaceuticals, Inc. to Report Clinical and Preclinical Data with DCC-2618 at the Upcoming 2018 American Association for Cancer Research (AACR) Annual Meeting Read More »
Deciphera Pharmaceuticals Initiates Phase 3 Clinical Study with DCC-2618 in Patients with Advanced Gastrointestinal Stromal Tumors (“INVICTUS” study) Read More »
Deciphera Pharmaceuticals, Inc. to Present at the 36th Annual J.P. Morgan Healthcare Conference Read More »